Vivos Therapeutics, Inc.
- Open
- 0.42
- Day high
- 0.44
- Day low
- 0.40
- Prev close
- 0.42
- Volume
- 239K
- Mkt cap
- $6M
- P/E (TTM)
- —
- EPS (TTM)
- —
- P/B
- -4.9
- P/S
- 0.3
- Yield
- —
- Per share
- —
Vivos Therapeutics, Inc. (VVOS) is a Healthcare company listed on NASDAQ. The stock is down 94% over the past year.
Vivos Therapeutics, Inc. (VVOS) financials & analyst ratings
Fundamentals (TTM)
Analyst consensus · 2 analysts
Source: exchange market data + company filings. Figures are trailing-twelve-month or as most recently reported. For informational purposes only — not investment advice.
VVOS earnings date, history & EPS estimates
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| May 20, 2026 | $-0.45 | $-0.52 | -15.6% | $5M | +18.2% |
| Nov 19, 2025 | $-0.53 | $-0.49 | +7.5% | $7M | -4.4% |
| Aug 19, 2025 | $-0.27 | $-0.55 | -103.7% | $4M | +4.6% |
| May 15, 2025 | $-0.44 | $-0.45 | -2.3% | $3M | -17.7% |
| Mar 31, 2025 | $-0.43 | $-0.28 | +34.9% | $4M | -4.8% |
| Nov 14, 2024 | $-0.70 | $-0.40 | +42.9% | $4M | -0.7% |
| Aug 14, 2024 | $-1.05 | $-0.60 | +42.9% | $4M | +12.6% |
| May 14, 2024 | $-1.17 | $-1.63 | -39.3% | $3M | +0.3% |
| Nov 14, 2023 | $-3.12 | $-1.75 | +43.9% | $3M | -26.6% |
| Aug 16, 2023 | $-3.75 | $-3.75 | +0.0% | $3M | -18.0% |
| Jun 8, 2023 | $-4.25 | $-5.00 | -17.6% | $4M | -7.1% |
| Dec 20, 2022 | $-0.28 | $-8.25 | -2846.4% | $4M | +14.1% |
VVOS insider trading activity (SEC Form 4)
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Apr 2, 2026 | Skaff Michael C10 percent owner | Buy | 308,848 | $1.34 |
| Apr 2, 2026 | Skaff Michael C10 percent owner | Buy | 1,044,777 | $1.34 |
| Apr 2, 2026 | Skaff Michael C10 percent owner | Buy | 1,783,582 | $1.09 |
| Apr 2, 2026 | Skaff Michael C10 percent owner | Buy | 429,957 | $0.00 |
| Nov 27, 2024 | Amman Bradford K.officer: Chief Financial Officer | Grant | 149,533 | $2.64 |
| Nov 27, 2024 | Huntsman Ronald Kirkdirector, officer: Chief Executive Officer | Grant | 315,421 | $2.64 |
| Jun 28, 2024 | Green Ralph Eliasdirector | Grant | 4,000 | $2.38 |
| Jun 28, 2024 | Amman Bradford K.officer: Chief Financial Officer | Grant | 15,000 | $2.38 |
| Jun 28, 2024 | Lindsay Mark F.director | Grant | 4,000 | $2.38 |
| Jun 28, 2024 | Thompson Matthewdirector | Grant | 4,000 | $2.38 |
| Jun 28, 2024 | Krammer Anja Bdirector | Grant | 4,000 | $2.38 |
| Jun 28, 2024 | Huntsman Ronald Kirkdirector, officer: Chief Executive Officer | Grant | 20,000 | $2.38 |
| Jun 28, 2024 | SOKOLOW LEONARD Jdirector | Grant | 4,000 | $2.38 |
| Jun 20, 2023 | Huntsman Ronald Kirkdirector, officer: Chief Executive Officer | Buy | 5,000 | $0.53 |
| Jun 20, 2023 | Huntsman Ronald Kirkdirector, officer: Chief Executive Officer | Buy | 21 | $0.50 |
Source: VVOS SEC Form 4 filings, latest Apr 2, 2026. For informational purposes only — not investment advice.
See the full VVOS insider & 13F page →Vivos Therapeutics, Inc. company profile
Overview
Vivos Therapeutics, Inc. (NASDAQ:VVOS) is a medical technology company founded in 2016 and based in Highlands Ranch, Colorado. The company went public in December 2020 and specializes in developing non-invasive treatment alternatives for patients suffering from dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring. Vivos has undergone significant strategic transformation since its founding, evolving from a dental-focused distribution model to a medical sleep center partnership approach, while maintaining its core focus on providing alternatives to traditional CPAP therapy for sleep apnea patients.
Business
Vivos Therapeutics operates in the sleep medicine and dental device industry, specifically targeting the treatment of obstructive sleep apnea (OSA) - a condition where breathing repeatedly stops and starts during sleep due to throat muscles relaxing and blocking the airway. This affects millions of Americans and traditionally requires patients to use bulky CPAP (Continuous Positive Airway Pressure) machines that force air through a mask worn during sleep. The company's primary offering is the Vivos System, a non-invasive, non-surgical, non-pharmaceutical treatment modality that uses custom-made oral appliances to gradually remodel the upper airway and facial structure. Unlike CPAP machines that provide temporary relief by forcing air through blocked airways, the Vivos System aims to create permanent structural changes that address the root cause of airway obstruction. The treatment involves wearing specially designed oral appliances that apply gentle pressure to expand the palate and reposition the jaw, ultimately enlarging the airway space. The company also offers the VivoScore Program, which provides screening and home sleep testing services for both adults and children. This diagnostic component helps identify patients who may benefit from Vivos treatment and provides an alternative to expensive, inconvenient overnight sleep lab studies. Vivos has recently expanded its product portfolio through the acquisition of intellectual property from Advanced Facialdontics, adding lower-cost treatment options and filling gaps in their product line. The company has also received FDA clearance for treating severe OSA in both adults and children, broadening its addressable patient population.
Revenue model
Vivos generates revenue through multiple streams within its sleep apnea treatment ecosystem. The primary revenue source is product sales of oral appliances, which generated $7.9 million in 2024 (approximately 53% of total revenue). The company manufactures and sells custom oral appliance arches to licensed dental professionals, primarily general dentists in the United States and Canada, who then provide treatment to patients. The second revenue stream comes from VIP enrollment fees paid by dental practitioners who want to become certified Vivos providers. These dentists pay enrollment fees and receive training, marketing support, and ongoing consultation services. In 2024, VIP enrollment revenue was approximately $4.2 million. The company is undergoing a strategic pivot toward a medical partnership model where it collaborates with sleep testing centers and medical providers. Under this model, Vivos expects to generate approximately $4,500 per patient case, with the company retaining 50% or better net contribution margins after sharing revenue with medical partners. This represents a shift from selling devices to dentists toward providing comprehensive treatment solutions through medical channels. Factors that could increase margins include successful expansion of the medical partnership model, which offers higher per-patient revenue and better conversion rates (70-80% vs. traditional dental channels), increased insurance reimbursement adoption following new Medicare codes, and economies of scale as manufacturing volumes increase. Margin pressures could arise from increased competition in the oral appliance market, pricing pressure from insurance providers, higher manufacturing costs, or the need to share more revenue with medical partners to secure strategic alliances.
Competitive moat
Vivos Therapeutics operates in a competitive landscape with limited sustainable competitive advantages. The company's primary moat lies in its intellectual property portfolio and clinical expertise in airway remodeling, particularly following its acquisition of Advanced Facialdontics patents. The Vivos System's approach of permanent airway remodeling rather than temporary symptom management differentiates it from traditional CPAP therapy and other oral appliances that simply hold the jaw in position. However, this moat is relatively narrow. The oral appliance market for sleep apnea includes numerous competitors, and the fundamental concept of jaw repositioning devices is well-established. The company's FDA clearances for severe OSA treatment provide some regulatory protection, but similar approvals can be obtained by competitors with sufficient clinical data. The company's growing network of trained providers and strategic partnerships with sleep centers could create some switching costs and network effects, but these are not insurmountable barriers. The sleep medicine market is large and fragmented, with multiple treatment modalities competing for market share. The most significant competitive threat comes from established medical device companies with greater resources, existing relationships with sleep centers, and proven reimbursement track records. ResMed, Philips, and other large players in the sleep medicine space could potentially develop competing solutions or acquire smaller competitors. Additionally, improvements in CPAP technology or alternative treatments could reduce demand for oral appliances. The company's small size and limited financial resources make it vulnerable to well-funded competitors entering the market.
Risks & safety
The margin of safety appears concerning based on current financial metrics and cash burn trajectory. • Liquidity risk: $2.3 million cash as of Q1 2025, with quarterly cash burn of approximately $3.8 million, suggesting less than one quarter of runway without additional financing • Working capital deficit: Current ratio of 0.77, indicating current liabilities exceed current assets by $1.1 million • Debt levels: Moderate debt-to-equity ratio of 0.32, but seeking additional $7.5 million senior loan financing • Valuation metrics: Trading at 5.6x book value despite negative earnings and cash flow; EV/EBITDA not meaningful due to negative EBITDA • Operating performance: Negative 88% return on equity, persistent operating losses despite revenue growth • Other considerations: Company expects to achieve cash flow positive status by end of 2025 through strategic acquisitions and partnerships, but execution risk remains high given limited financial resources and competitive market dynamics
Recent development
Over the past few years, Vivos has undergone a significant strategic transformation from a dental-focused distribution model to a medical sleep center partnership approach. The company initially built its business around enrolling dentists as Vivos Integrated Practitioners (VIPs) who would provide treatment directly to patients. However, management recognized that this model had limitations in terms of patient access and conversion rates. The pivotal strategic shift began in 2024 with the launch of strategic alliances with sleep testing centers, starting with Rebis Healthcare in Colorado. This medical-focused approach targets sleep centers with large patient databases, offering comprehensive OSA treatment alternatives. The company discovered that 70-80% of patients prefer Vivos treatment over traditional CPAP therapy when presented with the option. Key regulatory achievements include obtaining FDA clearance for treating severe OSA in both adults and children, and securing new Medicare reimbursement codes for Vivos devices. These developments opened doors to medical community collaboration and provided additional payment options for patients. The company has also pursued strategic acquisitions, including the pending acquisition of Sleep Center of Nevada (SCN) for $9 million, which is expected to test 3,000 patients monthly with 90% testing positive for OSA. This represents a shift toward vertical integration in the sleep medicine value chain. Product development efforts have focused on expanding the treatment portfolio through the Advanced Facialdontics acquisition, which added lower-cost treatment options and filled gaps in the product line. The company has also developed the VivoScore Program for home sleep testing and launched pediatric treatment capabilities.
VVOS company profile · for informational purposes only — not investment advice.
Track VVOS with Drillr
SEC filings, earnings calls, insider activity, alt-data signals — all queryable through Drillr's AI terminal and MCP API.
Try Drillr for free